Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation) (DECIDE)

Conor Medsystems

Status and phase

Terminated

Phase 4

Conditions

Coronary Artery Disease

Treatments

Device: CoStar Paclitaxel-eluting coronary stent system

Study type

Interventional

Funder types

Industry

Identifiers

NCT00440674

The DECIDE Trial: CP-05

Details and patient eligibility

About

The primary objective of this study is to evaluate the safety and effectiveness of a direct stenting technique compared to conventional stenting with pre-dilatation strategy using the CoStar Paclitaxel-eluting coronary stent system for the treatment of a single de novo lesion in a native coronary artery ≤ 25 mm long in a native coronary artery 2.5-3.5 mm diameter.

Full description

Prospective, multi-center, randomized (1:1), open-label study to evaluate direct stenting compared to conventional stenting with pre-dilatation strategy in treatment of a single de novo Lesion of a single native coronary artery in patients undergoing elective percutaneous coronary intervention.

Enrollment

18 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Eligible for percutaneous coronary intervention
Documented stable or unstable angina pectoris or with documented ischemia, or with documented silent ischemia
Left ventricular ejection fraction (LVEF) ≥25% documented within the last 6 weeks
Acceptable candidate for coronary artery bypass graft surgery
Single target vessel / single target lesion to be treated
Target lesion may be composed of multiple lesions but must be completely coverable by one (1) study stent
Cumulative target lesion length per vessel is ≤ 25 mm
RVD of 2.5-3.5 mm
Target lesion diameter stenosis ≥ 50% and < 100%
Target vessel has not undergone prior revascularization within the preceding 6 months

Exclusion criteria

Known sensitivity to cobalt chromium, Paclitaxel or PLGA
Acute MI within 72 hours prior to the index procedure as defined by the presence of a new pathologic Q-wave, or a creatine kinase (CK) level of > 2x the laboratory upper limits of normal and elevated MB
The patient is in cardiogenic shock
Cerebrovascular Accident (CVA) within the past 6 months
Acute or chronic renal dysfunction (creatinine > 2.0 mg/dL or > 150 µmol/L)/
Contraindication to ASA or to Clopidogrel
Thrombocytopenia (platelet count <100,000/mm3)
Active gastrointestinal (GI) bleeding within the past three months
Any prior true anaphylactic reaction to contrast agents
Patient is currently taking Colchicine
Patient is currently, or has been treated with Paclitaxel (systemic) within12 months of the index procedure
Comorbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
Left main coronary artery disease (stenosis >50%), whether protected or unprotected.
Target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >2.0 mm in diameter that requires intervention.
Target lesion is totally occluded Thrombolysis In MI (TIMI flow ≤1).
The target vessel has had prior drug-eluting stent placement to vessel segment (or branch) proximal to intended target lesion site.
Angiographic restenosis of any segment of the target vessel that has undergone prior PCI.
Angiographic evidence of atherosclerotic disease with >50% diameter stenosis (by visual estimate) proximal or distal to the target lesion (applies to the major epicardial portion of the target vessel and contiguous vessel segment if the target lesion is located in a branch vessel)